Product Overview
[Drug Name]
Generic Name: Ilaprazole Enteric-Coated Tablets
Trade Name: YiLiAn Ilaprazole Enteric-Coated Tablets 5mg*6 Tablets
Pinyin Code: YiLiAn AiPuLaZuoChangRongPian 5mg*6 Tablets
[Main Ingredients]
Main Ingredient: Ilaprazole Chemical Name: 5-(1H-pyrrol-1-yl)-2-[[(4-methoxy-3-methyl)-2-pyridinyl]-methyl]-sulfinyl-1H-benzimidazole Molecular Formula: C₁₆H₁₆N₄O₂S Molecular Weight: 366.43
[Properties]
This product is an enteric-coated tablet that appears white or off-white after removal of the coating.
[Indications/Main Functions]
This product is indicated for the treatment of duodenal ulcers and reflux esophagitis.
[Specifications]
5mg*6 tablets
[Dosage and Administration]
This product is indicated for the treatment of duodenal ulcers and reflux esophagitis in adults. Take orally in the morning on an empty stomach (do not chew). Duodenal ulcer: 5-10mg once daily for 4 weeks, or as directed by a physician. Reflux esophagitis: 10mg once daily for 4 weeks. For patients who have not recovered, an additional 4 weeks of treatment is recommended. For patients who have recovered but continue to experience symptoms, 5mg daily can be taken for an additional 4 weeks, or as directed by a physician.
[Adverse Reactions]
See package insert for details.
[Contraindications]
This product is contraindicated in patients with allergies to any of the ingredients in this product. It is contraindicated in patients with allergies to ilaprazole and other benzimidazole compounds.
[Precautions]
1. Do not chew or crush this product; swallow the tablet whole. 2. This product has a strong inhibitory effect on gastric acid secretion. Long-term, high-dose use is not recommended for general peptic ulcers and other conditions. 3. Malignant lesions of the stomach and esophagus should be ruled out before use to avoid delaying diagnosis due to symptom relief. 4. Because clinical research data on patients with hepatic and renal insufficiency are insufficient, patients with hepatic and renal insufficiency should use it with caution. Patients taking proton pump inhibitors for a long time should pay attention to the possible risk of fractures, especially elderly patients, and regularly monitor blood magnesium levels to prevent the occurrence of hypomagnesemia. 6. Patients who are using clopidogrel drugs should pay attention to drug interactions with proton pump inhibitors and communicate with their doctors about medication safety issues before treatment to ensure medication safety. 7. Clostridium difficile-associated diarrhea Published observational studies have shown that PPI treatment may increase the risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients. If diarrhea does not improve, this diagnosis should be considered.
